



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/484,704	01/18/2000	Kelly J. Henrickson	650053.91126	1001

26710 7590 01/27/2003

QUARLES & BRADY LLP
411 E. WISCONSIN AVENUE
SUITE 2040
MILWAUKEE, WI 53202-4497

[REDACTED] EXAMINER

SIEW, JEFFREY

ART UNIT	PAPER NUMBER
1637	21

DATE MAILED: 01/27/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/484,704	HENRICKSON ET AL.	
	Examiner	Art Unit	
	Jeffrey Siew	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 11/20/22.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 34-36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 34-36 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
. | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Request for Continued Examination

1. The request filed on 11/20/02 for a Request for Continued Examination (RCE) under 37 CFR 114 is acceptable. An action on the RCE follows.

Terminal Disclaimer

2. The terminal disclaimer filed on 9/26/02 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US5,744,299 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 34-36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- A) The term “substantially” renders claims 34-37 indefinite. It is unclear as to what degree the term would encompass and by what criteria , the term is measured.

Claim Rejections - 35 USC § 103

4. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

5. Claims 34-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Karron et al (J. Clinical Micro vol. 32 no. 2 pp. 484-88 1994) in view of Wu et al (EP0418960 A2 March 27, 1991) in further view of Sninsky et al (US5,176,995 Jan. 5, 1993).

Karron teach PCR rapid detection of HPIV-3 of HN gene using RT-PCR (see whole doc. esp. abstract).

Karron do not teach protein linked probe nor unequal primer concentration.

Wu et al teach a method of performing polymerase chain reaction using unequal primer concentration in which primer pairs is at least 2:1 (see abstract). They teach a polymerase reaction in which denaturation is performed thirty times at 95C.

Sninsky et al teach detection by hybridizing with a probe that is complementary to conserved nucleic acid sequence to genome of virus (see col. 15 line 40-45) and using biotin labeled probes (see col. 16 line 9).

One of ordinary skill in the art would have been motivated to apply Wu et al's primer ratios to Karron's method in order to successfully amplify the virus nucleic acid. As Wu et al teach that unequal primer ratio of 2:1 would lead to successful amplification, it would have been

Art Unit: 1656

prima facie obvious to apply Wu et al's ratios to Karron's method in order to maximize the amplification of viral nucleic acid.

Moreover, one of ordinary skill in the art would have been motivated to apply Sninsky et al's teaching of biotin labeled probes to Karron's detection method in order to quickly detect amplified virus. As biotin label probes allow rapid colorization, it would have been prima facie obvious to apply Sninsky et al's teaching of biotin probes to the Karron's detection method in order to rapidly detect viral sequences without the use of harmful radioactivity.

REBUTTAL

6. The response filed 11/20/02 has been fully considered and deemed not persuasive. The office would like to thank the response for noting the typographical omission of Wu et al from the 103 rejection heading. The rejection heading has been corrected. The response states that Wu et al do not teach a double stranded product is formed but that asymmetric PCR forms a single stranded product. While the office does not disagree that a single stranded product is formed, the double stranded product is also formed during the course of amplification (see EP 0418960 A page 6 lines 11-15 & page 3 line 26). The excess primer does allow single stranded to be formed for detection. However, predominantly leading up to final excess single stranded product is the formation of double strand product (see page 6 lines 11-15 & 21). Wu et al also states that their invention is useful for detection of specific nucleic acid having two complementary strands (see page 4 line 41) and that double stranded product is formed (see (col. 5 line 11-12). As the term "substantially" has been deemed indefinite, it does not distinguish the method over the prior art. Wu et al also teach multiplex reaction (see page 3 lines 20). The rejections are maintained.

SUMMARY

7. No claims allowed.

CONCLUSION

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey.Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner is on flex-time schedule and can best be reached on weekdays from 6:30 a.m. to 3 p.m. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703)-308-1119.

Any inquiry of a general nature, matching or filed papers or relating to the status of this application or proceeding should be directed to the Tracey Johnson for Art Unit 1637 whose telephone number is (703)-305-2982.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Before Final FAX (703) 872-9306 or After Final FAX (703) 30872-9307.


JEFFREY SIEW
PRIMARY EXAMINER

January 22, 2003